NORWALK, Conn. & LEXINGTON, Mass.--(BUSINESS WIRE)--The Multiple Myeloma Research Consortium (MMRC) today announced the start of a clinical trial evaluating ganetespib, a second generation Hsp90 inhibitor being developed by Synta Pharmaceuticals (NASDAQ: SNTA), as a single agent and in combination with the proteasome inhibitor bortezomib (VELCADE®) for the treatment of relapsed multiple myeloma.
